Furthermore, in the US, a three-year data of 263 members showed that Ribociclib plus Letrozole seemed to be an effective and economical approach for HR+/ HER2- advanced breast cancer patients13, 14. The gene discussed is ERBB2; the disease is breast carcinoma.